Two new drugs, developed by a Taiwanese company for the treatment of schizophrenia and designated by the U.S. Food and Drug Administration (FDA) as breakthrough therapy, will undergo late stage trials this year, according to the company's founder and CEO.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan central bank raises 2025 GDP growth forecast to 4.55%
09/18/2025 10:58 PM - Politics
Taiwanese firm adopts drone inspired by Russia-Ukraine war experience
09/18/2025 10:42 PM - Politics
Taiwan showcases its indigenous, co-produced drones at Taipei expo
09/18/2025 10:18 PM - Politics
Weapons hot: Taipei defense expo showcases Taiwan's latest weaponry, drones
09/18/2025 09:26 PM - Politics
Indian space startups seek Taiwan defense partnerships at TADTE 2025
09/18/2025 09:25 PM